‘Trojan horse’ artificial enzyme smuggles unnatural reactions into cells – Chemistry World
|
‘Trojan horse’ artificial enzyme smuggles unnatural reactions into cells
Chemistry World One of the tools scientists use to expand the scope of enzymes is synthetic biology, relying on combining pre-existing cellular components. But just as you are limited in what you can build using a set of Lego blocks, synthetic biology is similarly … |
Wall Street Journal |
Reading Roundup: Robots, Hiring Time, CRISPR Wars, More
CALIFORNIA CRISPR Wars. UC Berkeley’s Jennifer Doudna has chalked up another award for her discovery of the revolutionary CRISPR-Cas9 gene-editing tool—and a big one at that. The Kavli Prize in nanoscience is worth $1 million and will be shared among the three … Science Prizes Add Intrigue to the Race for the NobelWall Street Journal |
|
The FDA Has Just Put The Brakes on a Major CRISPR Trial in Humans
ScienceAlert You’ve heard it before: CRISPR has the potential to change our lives for the better. But first, we have to give it a chance. In December, gene-editing company CRISPR Therapeutics announced a partnership with biotech company Vertex to develop CTX001, … |
MSR News Online |
CRISPR: life-changing, world-changing science that will revolutionize medicine
MSR News Online Dr. Crutchfield, my nephew said there may be a new treatment called CRISPR for hundreds of diseases. What in the world is CRISPR? CRISPR is science and medicine’s potential secret weapon for treating and preventing inherited diseases like sickle cell … |
IFLScience |
Revolutionary Stem Cell Therapy To Fix Broken Human Hearts Approved In Japan
IFLScience As reported by Nature News, scientists in Japan now have official permission to treat people with heart disease with stem cells. Led by cardiac surgeons at Osaka University, they’ll be used to regenerate damaged muscle, also a common feature post-heart … |
Forbes |
Bluebird Bio’s Killer T–Cells Have “Impressive” Results Against Myeloma
Forbes based Bluebird Bio and Summit, N.J.-based Celgene, is a form of CAR-T, short for chimeric antigen receptor T–cell, for the type of white blood cell and the modifications made to it. This CAR-T targets a protein found in multiple myeloma cells called B … Cellular Therapies for Multiple Myeloma: A Paradigm ShiftCancer Network Bluebird Bio CAR–T delays multiple myeloma progression by one year, but is that enough?STAT #ASCO18: Bluebird & Celgene’s CAR–T nears 1 year of PFS in multiple myelomaFierceBiotech Business Wire (press release) –Reuters all 7 news articles » |